adenine has been researched along with Waldenstrom Macroglobulinemia in 118 studies
Waldenstrom Macroglobulinemia: A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The survival of Waldenstrom macroglobulinemia (WM) tumor cells hinges on aberrant B-cell receptor (BCR) and MYD88 signaling." | 5.43 | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( Ailawadhi, S; Akhtar, S; Ansell, SM; Bashir, Y; Caulfield, TR; Chanan-Khan, A; Chitta, K; Cogen, D; Coleman, M; Edenfield, B; Hudec, R; Jiang, J; Linder, S; Martin, P; Novak, A; Paulus, A; Paulus, SM; Roy, V; Samuel, K; Tran, D; Witzig, T; Yousaf, H, 2016) |
| " Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, β blocker use, and aspirin use were independently associated with incident arrhythmias." | 3.91 | Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy. ( Armanious, M; Chavez, JC; Emole, J; Fradley, MG; Gliksman, M; Lee, DH; McLeod, H; Pinilla-Ibarz, J; Rhea, I; Schabath, MB; Shah, B; Viganego, F; Walko, C; Welter-Frost, A, 2019) |
| "We analyzed 160 young Waldenström Macroglobulinemia (WM) patients with a median age of 49 years (range 23-55 years), diagnosed between January 2000 and January 2019 in 14 Italian centers." | 2.94 | Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. ( Abbadessa, A; Arcaini, L; Benevolo, G; Corbingi, A; Del Fabro, V; Deodato, M; Dogliotti, I; Fabbri, N; Ferrari, A; Ferrero, S; Ferretti, VV; Frustaci, AM; Gentile, M; Greco, C; Klersy, C; Laurenti, L; Luminari, S; Merli, M; Motta, M; Musto, P; Piazza, F; Rizzi, R; Varettoni, M; Visco, C, 2020) |
| "Among patients with Waldenström's macroglobulinemia, the use of ibrutinib-rituximab resulted in significantly higher rates of progression-free survival than the use of placebo-rituximab, both among those who had received no previous treatment and among those with disease recurrence." | 2.87 | Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. ( Buske, C; Dimopoulos, MA; García-Sanz, R; Graef, T; Herbaux, C; Kastritis, E; Leblond, V; Li, J; Macdonald, D; Mahe, B; Matous, JV; Orsucci, L; Palomba, ML; Salman, Z; Shustik, C; Tam, C; Tedeschi, A; Treon, SP; Trotman, J, 2018) |
| "Waldenström macroglobulinemia (WM), an incurable B-cell malignancy, is sensitive to Bruton tyrosine kinase (BTK) inhibition with ibrutinib, a first-generation BTK inhibitor." | 2.87 | A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. ( Atwal, S; Buske, C; Cohen, A; Huang, J; LeBlond, V; Novotny, W; Owen, RG; Tam, CS; Tedeschi, A, 2018) |
| "Waldenström macroglobulinemia (WM) is a hematological malignancy; it is a monoclonal gammopathy, a disease characterized by presence of a monoclonal immunoglobulin in serum and/or urine." | 2.72 | Waldenström macroglobulinemia. ( Baďurová, K; Gregorová, J; Krejčí, M; Ševčíková, S; Vlachová, M, 2021) |
| "Waldenstrom's Macroglobulinemia (WM) is a rare, indolent lymphoplasmacytic lymphoma characterized by heterogeneous clinical and genomic profile." | 2.66 | The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia. ( Dimopoulos, MA; Fotiou, D; Gavriatopoulou, M; Ntanasis-Stathopoulos, I, 2020) |
| "Waldenström's Macroglobulinemia (WM) is an indolent lymphoma with uniquely distinct and heterogenous clinical and genomic profiles." | 2.66 | Emerging drugs for the treatment of Waldenström macroglobulinemia. ( Despina, F; Efstathios, K; Meletios Athanasios, D, 2020) |
| "Waldenstrom macroglobulinemia (WM) is a rare type of non-Hodgkin lymphoma." | 2.61 | What is new in the treatment of Waldenstrom macroglobulinemia? ( Castillo, JJ; Treon, SP, 2019) |
| " Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas." | 2.61 | Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. ( Albrethsen, M; Chilkulwar, A; Faisal, MS; Fazal, S; Khattab, A; Sadashiv, S; Shaikh, H, 2019) |
| "Waldenström's macroglobulinemia (WM) is a rare, incurable hematologic disorder with a relatively indolent course in a majority of the patients." | 2.61 | Updates in prognostication and treatment of Waldenström's macroglobulinemia. ( Advani, P; Ailawadhi, S; Paulus, A, 2019) |
| "Waldenström macroglobulinemia is a rare indolent B-cell lymphoma." | 2.58 | Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond. ( Leleu, X; Magierowicz, M; Poulain, S; Tomowiak, C, 2018) |
| "Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation." | 2.58 | First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. ( Argyropoulos, KV; Palomba, ML, 2018) |
| "Waldenström macroglobulinemia (WM), an IgM-associated lymphoplasmacytic lymphoma, has witnessed several practice-altering advances in recent years." | 2.55 | Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. ( Ailawadhi, S; Ansell, SM; Bergsagel, PL; Braggio, E; Buadi, FK; Chanan-Khan, A; Colgan, JP; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Go, RS; Gonsalves, WI; Greipp, PT; Grogan, M; Habermann, TM; Hayman, SR; Hwa, YL; Inwards, DJ; Jevremovic, D; Johnston, PB; Kapoor, P; Ketterling, RP; King, RL; Kumar, SK; Kyle, RA; Lacy, MQ; Leung, N; Lin, Y; Lust, JA; Markovic, SN; Mauermann, M; Micallef, IN; Mikhael, JR; Morice, WG; Novak, A; Nowakowski, GS; Porrata, LF; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Sher, T; Stewart, AK; Thompson, CA; Witzig, TE; Zeldenrust, SR, 2017) |
| "Waldenström macroglobulinemia is defined by the presence of monoclonal immunoglobulin IgM type (M-IgM) and evidence of lymphoplasmacytic bone marrow infiltration." | 2.53 | [Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience]. ( Adam, Z; Král, Z; Krejčí, M; Mayer, J; Pour, L; Pourová, E; Ševčíková, E; Ševčíková, S, 2016) |
| "Waldenström macroglobulinemia (WM) is a rare lymphoma characterized by the accumulation of IgM-producing lymphoplasmacytic cells." | 2.53 | Future therapeutic options for patients with Waldenström macroglobulinemia. ( Argyropoulos, K; Castillo, JJ; Hunter, ZR; Palomba, ML; Treon, SP; Yang, G, 2016) |
| "Waldenström Macroglobulinemia (WM) is a rare B-cell lymphoma characterized by the uncontrolled accumulation of malignant lymphoplasmacytic cells, mainly in the bone marrow, and monoclonal IgM production." | 2.52 | Biology, prognosis, and therapy of Waldenström Macroglobulinemia. ( Castillo, JJ; Ghobrial, IM; Treon, SP, 2015) |
| "Waldenström macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells." | 2.52 | Ibrutinib for the treatment of Waldenström macroglobulinemia. ( Ansell, SM; Chakraborty, R; Gertz, MA; Kapoor, P, 2015) |
| "We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy." | 1.51 | Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. ( Ansell, SM; Buske, C; Castillo, JJ; Chavez, JC; Eyre, TA; Issa, S; Itchaki, G; Nayak, L; Palomba, ML; Paludo, J; Pasvolsky, O; Shain, KH; Simpson, D; Talaulikar, D; Tam, CS; Tedeschi, A; Treon, SP; Varettoni, M, 2019) |
| " Additionally, debate exists regarding the recommended dosing strategy for ibrutinib for this indication with disease remission demonstrated at 560 mg and 420 mg." | 1.51 | Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report. ( Arnall, JR; Hartsell, L; Janes, A; Larck, C; Park, S, 2019) |
| "Reasons for discontinuation include: disease progression (n = 27; 14%), toxicity (n = 15; 8%), nonresponse (n = 5; 3%), and other unrelated reasons (n = 4; 2%)." | 1.48 | Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. ( Castillo, JJ; Dubeau, T; Guang, Y; Gustine, JN; Hunter, ZR; Meid, K; Severns, P; Treon, SP; Xu, L, 2018) |
| "Chylothorax is an unusual cause of pleural effusion, typically caused by trauma or malignancy." | 1.46 | Recurrent chylothorax: a clinical mystery. ( Dalal, B; Dogra, S; Meka, SG; Otoupalova, E, 2017) |
| "The survival of Waldenstrom macroglobulinemia (WM) tumor cells hinges on aberrant B-cell receptor (BCR) and MYD88 signaling." | 1.43 | Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( Ailawadhi, S; Akhtar, S; Ansell, SM; Bashir, Y; Caulfield, TR; Chanan-Khan, A; Chitta, K; Cogen, D; Coleman, M; Edenfield, B; Hudec, R; Jiang, J; Linder, S; Martin, P; Novak, A; Paulus, A; Paulus, SM; Roy, V; Samuel, K; Tran, D; Witzig, T; Yousaf, H, 2016) |
| "Waldenström macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells." | 1.42 | How I treat Waldenström macroglobulinemia. ( Treon, SP, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.85) | 29.6817 |
| 2010's | 79 (66.95) | 24.3611 |
| 2020's | 38 (32.20) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, JJ | 41 |
| Meid, K | 16 |
| Gustine, JN | 12 |
| Leventoff, C | 2 |
| White, T | 2 |
| Flynn, CA | 6 |
| Sarosiek, S | 8 |
| Demos, MG | 7 |
| Guerrera, ML | 9 |
| Kofides, A | 10 |
| Liu, X | 16 |
| Munshi, M | 10 |
| Tsakmaklis, N | 15 |
| Xu, L | 20 |
| Yang, G | 21 |
| Branagan, AR | 5 |
| O'Donnell, E | 1 |
| Raje, N | 1 |
| Yee, AJ | 1 |
| Patterson, CJ | 13 |
| Hunter, ZR | 23 |
| Treon, SP | 45 |
| Buske, C | 12 |
| Tedeschi, A | 8 |
| Trotman, J | 9 |
| García-Sanz, R | 5 |
| MacDonald, D | 4 |
| Leblond, V | 6 |
| Mahe, B | 3 |
| Herbaux, C | 3 |
| Matous, JV | 5 |
| Tam, CS | 8 |
| Heffner, LT | 3 |
| Varettoni, M | 5 |
| Palomba, ML | 11 |
| Shustik, C | 4 |
| Kastritis, E | 5 |
| Ping, J | 2 |
| Hauns, B | 2 |
| Arango-Hisijara, I | 2 |
| Dimopoulos, MA | 7 |
| Parrondo, RD | 1 |
| Paulus, A | 5 |
| Alegria, V | 1 |
| Liebowitz, D | 1 |
| Johnson, C | 1 |
| Clynes, R | 1 |
| Roy, V | 4 |
| Menke, DM | 1 |
| Jiang, L | 2 |
| Chanan-Khan, AA | 2 |
| Ailawadhi, S | 6 |
| Baďurová, K | 1 |
| Gregorová, J | 1 |
| Vlachová, M | 1 |
| Krejčí, M | 2 |
| Ševčíková, S | 2 |
| Sarosiek, SR | 2 |
| Leventoff, CR | 2 |
| White, TP | 2 |
| Ferrero, S | 2 |
| Gentile, M | 2 |
| Laurenti, L | 2 |
| Mauro, FR | 1 |
| Martelli, M | 1 |
| Sportoletti, P | 1 |
| Visco, C | 2 |
| Zinzani, PL | 1 |
| Elamin, G | 1 |
| Aljoundi, A | 1 |
| Alahmdi, MI | 1 |
| Abo-Dya, NE | 1 |
| Soliman, MES | 1 |
| Büyükkurt, N | 1 |
| Soydaş, B | 1 |
| Ambinder, AJ | 1 |
| Hambley, B | 1 |
| Shanbhag, S | 1 |
| Merrill, SA | 1 |
| Abeykoon, JP | 2 |
| Zanwar, S | 2 |
| Ansell, SM | 7 |
| Gertz, MA | 5 |
| Kumar, S | 1 |
| Manske, M | 1 |
| Novak, AJ | 1 |
| King, R | 2 |
| Greipp, P | 1 |
| Go, R | 1 |
| Inwards, D | 1 |
| Muchtar, E | 1 |
| Habermann, T | 1 |
| Witzig, TE | 3 |
| Thompson, CA | 2 |
| Dingli, D | 2 |
| Lacy, MQ | 2 |
| Leung, N | 2 |
| Dispenzieri, A | 2 |
| Gonsalves, W | 1 |
| Warsame, R | 1 |
| Kyle, RA | 2 |
| Rajkumar, V | 1 |
| Parikh, SA | 1 |
| Kapoor, P | 4 |
| Chen, JG | 5 |
| Chan, GG | 4 |
| Keezer, A | 2 |
| Dubeau, T | 5 |
| Jiménez, C | 1 |
| Chen, J | 5 |
| Wiestner, A | 1 |
| Castellani, F | 1 |
| Visentin, A | 1 |
| Campagnolo, M | 1 |
| Salvalaggio, A | 1 |
| Cacciavillani, M | 1 |
| Candiotto, C | 1 |
| Bertorelle, R | 1 |
| Trentin, L | 1 |
| Briani, C | 1 |
| Skarbnik, AP | 1 |
| Soumerai, JD | 1 |
| Ghobrial, IM | 5 |
| Lim, KJC | 2 |
| Gavriatopoulou, M | 1 |
| Fotiou, D | 1 |
| Ntanasis-Stathopoulos, I | 1 |
| Barnes, M | 1 |
| Sharma, P | 1 |
| Kumar, V | 1 |
| Kaell, A | 1 |
| LiPera, W | 1 |
| Pabon, CM | 1 |
| Neff, JL | 1 |
| Forns, TE | 1 |
| Wang, J | 1 |
| Opat, S | 1 |
| D'Sa, S | 1 |
| Jurczak, W | 2 |
| Lee, HP | 1 |
| Cull, G | 1 |
| Owen, RG | 2 |
| Marlton, P | 1 |
| Wahlin, BE | 1 |
| Sanz, RG | 1 |
| McCarthy, H | 1 |
| Mulligan, S | 1 |
| Czyz, J | 1 |
| Fernández de Larrea, C | 1 |
| Belada, D | 1 |
| Libby, E | 1 |
| Motta, M | 2 |
| Siddiqi, T | 1 |
| Tani, M | 1 |
| Trneny, M | 1 |
| Minnema, MC | 2 |
| Chan, WY | 1 |
| Schneider, J | 1 |
| Ro, S | 1 |
| Cohen, A | 2 |
| Huang, J | 2 |
| Dimopoulos, M | 1 |
| Ferrari, A | 1 |
| Frustaci, AM | 1 |
| Ferretti, VV | 1 |
| Rizzi, R | 1 |
| Piazza, F | 1 |
| Merli, M | 1 |
| Benevolo, G | 1 |
| Del Fabro, V | 1 |
| Abbadessa, A | 1 |
| Klersy, C | 1 |
| Musto, P | 1 |
| Fabbri, N | 1 |
| Deodato, M | 1 |
| Dogliotti, I | 1 |
| Greco, C | 1 |
| Corbingi, A | 1 |
| Luminari, S | 1 |
| Arcaini, L | 1 |
| Gustine, J | 2 |
| Laubach, JP | 2 |
| Advani, R | 3 |
| de Jong, J | 1 |
| Mitselos, A | 1 |
| Cordoba, R | 1 |
| Panizo, C | 1 |
| Wrobel, T | 1 |
| Dlugosz-Danecka, M | 1 |
| Jiao, J | 1 |
| Sukbuntherng, J | 1 |
| Ouellet, D | 1 |
| Hellemans, P | 1 |
| Despina, F | 1 |
| Meletios Athanasios, D | 1 |
| Efstathios, K | 1 |
| Xia, Y | 1 |
| Zhu, HY | 1 |
| Wang, L | 1 |
| Chen, RZ | 1 |
| Chen, W | 1 |
| Ding, CY | 1 |
| Xu, W | 1 |
| Li, JY | 1 |
| Vitolo, U | 1 |
| Novo, M | 1 |
| Santambrogio, E | 1 |
| Mein, K | 1 |
| Advani, RH | 2 |
| Matissek, SJ | 1 |
| Han, W | 1 |
| Karbalivand, M | 1 |
| Sayed, M | 1 |
| Reilly, BM | 1 |
| Mallat, S | 1 |
| Ghazal, SM | 1 |
| Walker, SR | 1 |
| Elsawa, SF | 1 |
| Chien, HC | 1 |
| Morreall, D | 1 |
| Patil, V | 1 |
| Rasmussen, KM | 1 |
| Yong, CM | 1 |
| Li, CY | 1 |
| Passey, DG | 1 |
| Burningham, Z | 1 |
| Sauer, BC | 1 |
| Halwani, AS | 1 |
| Maynard, S | 1 |
| Ros-Soto, J | 1 |
| Chaidos, A | 1 |
| Innes, A | 1 |
| Paleja, K | 1 |
| Mirvis, E | 1 |
| Buti, N | 1 |
| Sharp, H | 1 |
| Palanicawandar, R | 1 |
| Milojkovic, D | 1 |
| Bouffard, MA | 1 |
| Chwalisz, BK | 1 |
| Romero, JM | 1 |
| Arrillaga-Romany, IC | 1 |
| Massoth, LR | 1 |
| Demos, M | 2 |
| Cao, Y | 5 |
| Roccaro, AM | 1 |
| Sacco, A | 1 |
| LaMacchia, J | 1 |
| Pozdnyakova, O | 1 |
| Helber, MJ | 1 |
| Moore, JE | 1 |
| Williams, AM | 1 |
| Meacham, PJ | 1 |
| Rothberg, PG | 1 |
| Zent, CS | 1 |
| Baron, M | 1 |
| Zini, JM | 1 |
| Challan Belval, T | 1 |
| Vignon, M | 1 |
| Denis, B | 1 |
| Alanio, A | 1 |
| Malphettes, M | 1 |
| Kahn, A | 1 |
| Horsley-Silva, JL | 1 |
| Lam-Himlin, DM | 1 |
| Reeder, CB | 2 |
| Douglas, DD | 1 |
| Carey, EJ | 1 |
| Ali, N | 1 |
| Malik, F | 1 |
| Jafri, SIM | 1 |
| Naglak, M | 1 |
| Sundermeyer, M | 1 |
| Pickens, PV | 1 |
| Vos, JM | 1 |
| Brodsky, P | 1 |
| Ganz, T | 1 |
| Pals, ST | 2 |
| Kersten, MJ | 2 |
| Hiemcke-Jiwa, LS | 1 |
| Leguit, RJ | 1 |
| Radersma-van Loon, JH | 1 |
| Westerweel, PE | 1 |
| Rood, JJM | 1 |
| Doorduijn, JK | 1 |
| Huibers, MMH | 1 |
| Otoupalova, E | 1 |
| Meka, SG | 1 |
| Dogra, S | 1 |
| Dalal, B | 1 |
| Severns, P | 2 |
| Guang, Y | 1 |
| Boudin, L | 1 |
| Patient, M | 1 |
| Roméo, E | 1 |
| Bladé, JS | 1 |
| de Jauréguiberry, JP | 1 |
| Dubeau, TE | 4 |
| Palomba, L | 1 |
| Tam, C | 2 |
| Orsucci, L | 1 |
| Li, J | 3 |
| Salman, Z | 3 |
| Graef, T | 3 |
| Novotny, W | 1 |
| Atwal, S | 1 |
| Killock, D | 1 |
| Tappenden, P | 1 |
| Carroll, C | 1 |
| Stevens, J | 1 |
| Simpson, E | 1 |
| Thokala, P | 1 |
| Wong, R | 1 |
| Wright, J | 1 |
| Auer, R | 1 |
| Yosef, A | 1 |
| Touloukian, EZ | 1 |
| Nambudiri, VE | 1 |
| Shaikh, H | 1 |
| Khattab, A | 1 |
| Faisal, MS | 1 |
| Chilkulwar, A | 1 |
| Albrethsen, M | 1 |
| Sadashiv, S | 1 |
| Fazal, S | 1 |
| Manna, A | 1 |
| Akhtar, S | 2 |
| Paulus, SM | 2 |
| Sharma, M | 1 |
| Coignet, MV | 1 |
| Allan, J | 1 |
| Furman, R | 1 |
| Aulakh, S | 1 |
| Manochakian, R | 1 |
| Sher, T | 2 |
| Magierowicz, M | 1 |
| Tomowiak, C | 1 |
| Leleu, X | 1 |
| Poulain, S | 2 |
| Argyropoulos, KV | 2 |
| Tallant, A | 1 |
| Selig, D | 1 |
| Wanko, SO | 1 |
| Roswarski, J | 1 |
| Plander, M | 1 |
| Szendrei, T | 1 |
| Vadvári, Á | 1 |
| Iványi, J | 1 |
| Dolgin, E | 1 |
| Olszewski, AJ | 1 |
| Cavazzini, F | 1 |
| Rigolin, GM | 1 |
| Cuneo, A | 1 |
| Cheng, MP | 1 |
| Kusztos, AE | 1 |
| Dryden-Peterson, SL | 1 |
| Woolley, AE | 1 |
| Hammond, SP | 1 |
| Baden, LR | 1 |
| Issa, NC | 1 |
| Itchaki, G | 1 |
| Paludo, J | 1 |
| Eyre, TA | 1 |
| Chavez, JC | 2 |
| Shain, KH | 1 |
| Issa, S | 1 |
| Pasvolsky, O | 1 |
| Simpson, D | 1 |
| Talaulikar, D | 2 |
| Nayak, L | 1 |
| Leskov, I | 1 |
| Knezevic, A | 1 |
| Gill, MK | 1 |
| Hartsell, L | 1 |
| Janes, A | 1 |
| Larck, C | 1 |
| Park, S | 1 |
| Arnall, JR | 1 |
| Advani, P | 1 |
| Grunenberg, A | 1 |
| Fradley, MG | 1 |
| Gliksman, M | 1 |
| Emole, J | 1 |
| Viganego, F | 1 |
| Rhea, I | 1 |
| Welter-Frost, A | 1 |
| Armanious, M | 1 |
| Lee, DH | 1 |
| Walko, C | 1 |
| Shah, B | 1 |
| McLeod, H | 1 |
| Pinilla-Ibarz, J | 1 |
| Schabath, MB | 1 |
| Hashmi, H | 1 |
| Dhanoa, JS | 1 |
| Emmons, R | 1 |
| Bernardeschi, P | 1 |
| Pirrotta, MT | 1 |
| Del Rosso, A | 1 |
| Fontanelli, G | 1 |
| Milandri, C | 1 |
| Moreno, DF | 1 |
| Arbelaez, MI | 1 |
| Brown, JR | 2 |
| Cameron, F | 1 |
| Sanford, M | 1 |
| Kanan, S | 4 |
| Rodig, S | 2 |
| Hatjiharissi, E | 1 |
| Davids, MS | 1 |
| Tripsas, CK | 1 |
| Warren, D | 1 |
| Varma, G | 1 |
| Green, R | 1 |
| Zehnder, JL | 1 |
| Aster, JC | 1 |
| Harris, NL | 1 |
| Ghobrial, I | 1 |
| Cheng, M | 1 |
| Clow, F | 1 |
| Bagcchi, S | 1 |
| Berglöf, A | 1 |
| Hamasy, A | 1 |
| Meinke, S | 1 |
| Palma, M | 1 |
| Krstic, A | 1 |
| Månsson, R | 1 |
| Kimby, E | 2 |
| Österborg, A | 1 |
| Smith, CI | 1 |
| Chakraborty, R | 1 |
| Smith, MR | 1 |
| Hunter, Z | 1 |
| de Rooij, MF | 1 |
| Kuil, A | 1 |
| Kraan, W | 1 |
| Spaargaren, M | 1 |
| Cabannes-Hamy, A | 1 |
| Lemal, R | 2 |
| Goldwirt, L | 1 |
| Amorim, S | 1 |
| Pérignon, R | 1 |
| Berger, J | 1 |
| Brice, P | 1 |
| De Kerviler, E | 1 |
| Bay, JO | 2 |
| Sauvageon, H | 1 |
| Beldjord, K | 1 |
| Mourah, S | 1 |
| Tournilhac, O | 3 |
| Thieblemont, C | 2 |
| Dougé, A | 1 |
| Ravinet, A | 1 |
| Guièze, R | 1 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Pourová, E | 1 |
| Ševčíková, E | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
| Buhrlage, SJ | 1 |
| Tan, L | 1 |
| Zhang, W | 1 |
| Zhang, X | 1 |
| Liu, S | 1 |
| Cohen, P | 1 |
| Gray, N | 1 |
| Tripathi, A | 1 |
| Steingart, R | 1 |
| Cea, M | 1 |
| Cagnetta, A | 1 |
| Acharya, C | 1 |
| Acharya, P | 1 |
| Tai, YT | 2 |
| Yang, C | 1 |
| Lovera, D | 1 |
| Soncini, D | 1 |
| Miglino, M | 1 |
| Fraternali-Orcioni, G | 1 |
| Mastracci, L | 1 |
| Nencioni, A | 1 |
| Montecucco, F | 1 |
| Monacelli, F | 1 |
| Ballestrero, A | 1 |
| Hideshima, T | 1 |
| Chauhan, D | 1 |
| Gobbi, M | 1 |
| Lemoli, RM | 1 |
| Munshi, N | 1 |
| Anderson, KC | 2 |
| Mason, C | 1 |
| Savona, S | 1 |
| Rini, JN | 1 |
| Allen, SL | 1 |
| Caulfield, TR | 1 |
| Samuel, K | 1 |
| Yousaf, H | 1 |
| Bashir, Y | 1 |
| Tran, D | 1 |
| Hudec, R | 1 |
| Cogen, D | 1 |
| Jiang, J | 1 |
| Edenfield, B | 1 |
| Novak, A | 2 |
| Witzig, T | 1 |
| Martin, P | 1 |
| Coleman, M | 1 |
| Chitta, K | 1 |
| Linder, S | 1 |
| Chanan-Khan, A | 3 |
| Argyropoulos, K | 1 |
| Cheson, BD | 1 |
| Ma, S | 1 |
| Oriol, A | 1 |
| Cornell, RF | 1 |
| de Larrea, CF | 1 |
| Granell, M | 1 |
| Kyrtsonis, MC | 1 |
| Symeonidis, A | 1 |
| Singh, P | 1 |
| Bilotti, E | 1 |
| Treon, S | 1 |
| Beyer, A | 1 |
| Ganti, B | 1 |
| Majkrzak, A | 1 |
| Theyyunni, N | 1 |
| Fonseca, R | 1 |
| Kumar, SK | 1 |
| Mikhael, JR | 1 |
| Mauermann, M | 1 |
| Stewart, AK | 1 |
| Buadi, FK | 1 |
| Morice, WG | 1 |
| Go, RS | 1 |
| Jevremovic, D | 1 |
| King, RL | 1 |
| Braggio, E | 1 |
| Ketterling, RP | 1 |
| Greipp, PT | 1 |
| Grogan, M | 1 |
| Micallef, IN | 1 |
| Bergsagel, PL | 1 |
| Colgan, JP | 1 |
| Gonsalves, WI | 1 |
| Lin, Y | 1 |
| Inwards, DJ | 1 |
| Hayman, SR | 1 |
| Nowakowski, GS | 1 |
| Johnston, PB | 1 |
| Russell, SJ | 1 |
| Markovic, SN | 1 |
| Zeldenrust, SR | 1 |
| Hwa, YL | 1 |
| Lust, JA | 1 |
| Porrata, LF | 1 |
| Habermann, TM | 1 |
| Rajkumar, SV | 1 |
| Joshua, D | 1 |
| Ho, JP | 1 |
| Szer, J | 1 |
| Quach, H | 1 |
| Spencer, A | 1 |
| Harrison, S | 1 |
| Mollee, P | 1 |
| Roberts, AW | 1 |
| Horvath, N | 1 |
| Lee, C | 1 |
| Zannettino, A | 1 |
| Brown, R | 1 |
| Augustson, B | 1 |
| Jaksic, W | 1 |
| Gibson, J | 1 |
| Kalff, A | 1 |
| Johnston, A | 1 |
| Kalro, A | 1 |
| Grigoriadis, G | 1 |
| Ward, C | 1 |
| Prince, HM | 1 |
| Furman, RR | 1 |
| Jerkeman, M | 1 |
| Hallek, M | 1 |
| Dreyling, M | 1 |
| Staudt, L | 1 |
| Khaled, Y | 1 |
| Hanbali, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing[NCT02604511] | Phase 2 | 31 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Phase II Clinical Study of Zanubrutinib Combined With Bendamustine and Rituximab (ZBR) for Time-limited Treatment of Waldenstrom Macroglobulinemia[NCT05914662] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-02-15 | Recruiting | ||
| iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia[NCT02165397] | Phase 3 | 181 participants (Actual) | Interventional | 2014-07-07 | Completed | ||
| Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| Clinical Research for Efficacy and Safety of Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission[NCT05596097] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-10-30 | Not yet recruiting | ||
| Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia[NCT01614821] | Phase 2 | 63 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy[NCT03301207] | Phase 1 | 25 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia[NCT03225716] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2017-10-20 | Active, not recruiting | ||
| A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)[NCT03053440] | Phase 3 | 201 participants (Actual) | Interventional | 2017-01-25 | Completed | ||
| Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392] | Phase 3 | 24 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia[NCT04463953] | Phase 2 | 55 participants (Anticipated) | Interventional | 2020-05-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To asses the percentage of participants with an Minor Response (MR) (25% reduction or more in serum IgM) or better. (NCT02604511)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib | 30 |
The amount of time between attainment of at least a minor response and disease progression. (NCT02604511)
Timeframe: 6 years
| Intervention | months (Median) |
|---|---|
| Ibrutinib | 46 |
To asses the percentage of participants with a Partial Response (PR) (50% reduction or more in serum IgM) or better. (NCT02604511)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib | 26 |
The number of participants who are still living 6 years after initiation of ibrutinib (NCT02604511)
Timeframe: 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib | 30 |
The number of participants who have not experienced disease progression 6 years after therapy initiation (NCT02604511)
Timeframe: 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib | 24 |
The amount of time between starting treatment and attaining at least a minor response to therapy (NCT02604511)
Timeframe: 4 years
| Intervention | months (Median) |
|---|---|
| Ibrutinib | 0.9 |
ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), very good partial response (VGPR), or partial response (PR) per the IRC assessment at or prior to initiation of subsequent antineoplastic therapy and confirmed by 2 consecutive assessments. IRC assessment of response was conducted according to the modified VIth IWWM (NCCN 2014) criteria and incorporated assessments from the central radiology review. CR required complete resolution of lymphadenopathy/splenomegaly if present at baseline. VGPR and PR required reduction in lymphadenopathy/splenomegaly if present at baseline.. Kaplan-Meier estimate. (NCT02165397)
Timeframe: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 76.0 |
| Placebo + Rituximab | 30.7 |
| Open-Label Substudy: Ibrutinib | 77.4 |
"OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.~As the median OS was not reached in any treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 54) are presented." (NCT02165397)
Timeframe: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 86.4 |
| Placebo + Rituximab | 84.2 |
| Open-Label Substudy: Ibrutinib | 73.4 |
Percentage of participants with ≥ 3 points increase from baseline by Week 25 in the FACIT-Fatigue subscale score.The FACIT-Fatigue is a 13-item questionnaire that assesses participant reported fatigue and its impact upon daily activities and function over the past 7 days. Each of the 13 items of the FACIT-Fatigue Scale ranges from 0-4, with a range of possible total scores from 0 (extreme fatigue) to 52 (no fatigue). Scores below 30 indicate severe fatigue. (NCT02165397)
Timeframe: Baseline, 25 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 68.0 |
| Placebo + Rituximab | 54.7 |
| Open-Label Substudy: Ibrutinib | 87.1 |
Percentage of participants achieving a sustained improvement in Hgb at or prior to initiation of subsequent antineoplastic therapy. Hgb improvement is defined as an increase of ≥ 2 g/dL over baseline regardless of baseline value, or an increase to >11 g/dL with a ≥0.5 g/dL improvement if baseline is ≤ 11 g/dL. Sustained Hgb improvement is defined as improvement that is sustained continuously for ≥ 56 days (8 weeks) without blood transfusion or growth factors, which includes hemoglobin > 110 g/L with at least a 5 g/L improvement if baseline ≤110 g/L or increase ≥20 g/L over baseline. (NCT02165397)
Timeframe: Median time on study: 49.7 months (Ibr+R and Pbo+R) and 57.9 months (Open-Label Ibr)
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 77.3 |
| Placebo + Rituximab | 42.7 |
| Open-Label Substudy: Ibrutinib | 71.0 |
"PFS was defined as the time from date randomization to date of first IRC-confirmed disease progression (PD) assessed according to the modified VIth International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria (National Comprehensive Cancer Network [NCCN] 2014) or death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death.~As the median PFS was not reached in the Ibrutinib + Rituximab arm at the time of the analysis, Kaplan Meier landmark estimate of the PFS rate at 54 months (that is, the estimated percentage of participants with PFS at Month 54) is presented." (NCT02165397)
Timeframe: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 68.0 |
| Placebo + Rituximab | 25.3 |
| Open-Label Substudy: Ibrutinib | 39.7 |
"TTnT was measured from the date of randomization to the start date of any subsequent WM treatment. Participants without subsequent treatment were censored at the date of the last study visit.~As the median TTnT was not reached in the Ibrutinib + Rituximab arm and the Open-Label Substudy arm at the time of the analysis, Kaplan Meier landmark estimate of the TTnT rate at 54 months (that is, the estimated percentage of participants not receiving subsequent WM treatment at Month 54) are presented." (NCT02165397)
Timeframe: Month 54 (median time on study: 49.7 months [Ibr+R and Pbo+R] and 57.9 months [Open-Label Ibr])
| Intervention | percentage of participants (Number) |
|---|---|
| Ibrutinib + Rituximab | 87.4 |
| Placebo + Rituximab | 29.4 |
| Open-Label Substudy: Ibrutinib | 64.6 |
To determine Progression Free Survival (PFS in symptomatic WM patients with relapsed/refractory disease. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. 40 participants were censored prior to disease progression. (NCT01614821)
Timeframe: 6 years
| Intervention | months (Median) |
|---|---|
| Treatment Arm | 39 |
To assess the major response rate (>50% reduction in serum IgM from baseline) (NCT01614821)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 49 |
To assess the overall response rate (>25% reduction in serum IgM from baseline). (NCT01614821)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 57 |
To assess the safety and tolerability of PCI-32765 in symptomatic WM patients with relapsed/refractory disease. Grade > or = 2 Adverse Events determined to be associated with PCI-32765 and subsequent outcomes will constitute the safety profile of PCI-32765 in WM. Percent of participants who experienced at least 1 grade 2 or higher treatment emergent adverse event. (NCT01614821)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 62 |
Time to Next Therapy is the duration of time from of starting ibrutinib until next therapy. Participants were treated for 40 cycles and then followed for 2 years or until next therapy or death. Participants had the option to continue ibrutinib commercially. 40 participants were censored while still on commercial ibrutinib therapy. (NCT01614821)
Timeframe: 6 years
| Intervention | months (Median) |
|---|---|
| Treatment Arm | 49 |
To assess the very good partial response rate (>90% reduction in serum IgM from baseline) (NCT01614821)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm | 17 |
DOR is defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first (NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Months (Median) |
|---|---|
| Arm A: Ibrutinib | NA |
| Arm B: Zanubrutinib | NA |
DOR defined as the time from first determination of response (CR, VGPR or PR) until first documentation of progression or death, whichever comes first. CR is defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, is defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) is defined as ≥50% reduction of serum IgM from baseline. (NCT03053440)
Timeframe: Up to approximately 2 years and 7 months
| Intervention | Months (Median) |
|---|---|
| Arm A: Ibrutinib | NA |
| Arm B: Zanubrutinib | NA |
Percentage of participants with CR, defined as normal serum immunoglobulin M (IgM) levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values. (NCT03053440)
Timeframe: Up to approximately 2 years and 7 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Arm A: Ibrutinib | 19.2 |
| Arm B: Zanubrutinib | 28.4 |
Percentage of participants with CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at Baseline, or VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values. (NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Arm A: Ibrutinib | 25.3 |
| Arm B: Zanubrutinib | 38.2 |
MRR defined as the percentage of participants achieving a best response of response of CR, defined as normal serum IgM levels, disappearance of monoclonal protein by immunofixation, and negative cryoglobulinemia if cryoglobulinemia was positive at baseline, VGPR, defined as ≥90% reduction in serum IgM level from baseline or normal serum IgM values or partial response (PR) defined as ≥50% reduction of serum IgM from baseline. (NCT03053440)
Timeframe: Up to approximately 2 years and 7 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Arm A: Ibrutinib | 77.8 |
| Arm B: Zanubrutinib | 77.5 |
Anti-Lymphoma Effect is defined as any reduction in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by CT scan, at any time during the course of study treatment. (NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Arm A: Ibrutinib | 84.2 |
| Arm B: Zanubrutinib | 78.8 |
(NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Arm A: Ibrutinib | 78.6 |
| Arm B: Zanubrutinib | 79.2 |
PFS as assessed by the Investigator, defined as time from randomization to the first documentation of progression (per modified IWWM criteria) or death, whichever occurs first. (NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Months (Median) |
|---|---|
| Arm A: Ibrutinib | NA |
| Arm B: Zanubrutinib | NA |
PFS as assessed by the IRC, defined as time from randomization to the first documentation of progression (per modified International Workshop on Waldenström macroglobulinemia [IWWM criteria]) or death, whichever occurs first (NCT03053440)
Timeframe: Up to approximately 2 years and 7 months
| Intervention | Months (Median) |
|---|---|
| Arm A: Ibrutinib | NA |
| Arm B: Zanubrutinib | NA |
Estimated percentage of participants who were event-free based on Kaplan-Meier method. (NCT03053440)
Timeframe: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| 12 Months | 18 Months | |
| Arm A: Ibrutinib | 87.9 | 87.9 |
| Arm B: Zanubrutinib | 94.4 | 85.2 |
Estimated percentage of participants who were event-free based on Kaplan-Meier method. (NCT03053440)
Timeframe: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| 24 Months | 36 Months | 48 Months | |
| Arm A: Ibrutinib | 87.7 | 77.5 | 73.9 |
| Arm B: Zanubrutinib | 89.7 | 81.1 | 81.1 |
(NCT03053440)
Timeframe: Up to approximately 5 years and 5 months
| Intervention | Number of Participants (Number) | |
|---|---|---|
| Participants with At Least 1 TEAE | Participants with SAEs | |
| Arm A: Ibrutinib | 98 | 50 |
| Arm B: Zanubrutinib | 101 | 59 |
Estimated percentage of participants who were event-free based on Kaplan-Meier method (NCT03053440)
Timeframe: 12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| 12 Months | 18 Months | |
| Arm A: Ibrutinib | 87.2 | 83.8 |
| Arm B: Zanubrutinib | 89.7 | 85.0 |
Percentage of participants who were event-free based on Kaplan-Meier method. (NCT03053440)
Timeframe: 24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| 24 Months | 36 Months | 48 Months | |
| Arm A: Ibrutinib | 80.6 | 74.8 | 67.3 |
| Arm B: Zanubrutinib | 88.5 | 78.3 | 78.3 |
33 reviews available for adenine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Myeloid Differentiation Factor 88; Piperidines | 2021 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Lymphoma, B-Cell; Piperidines; Protein Kinase | 2023 |
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Topics: Adenine; Humans; Quality of Life; Rituximab; Waldenstrom Macroglobulinemia | 2023 |
Novel Agents in Waldenström Macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Humans; Protein Kinase Inhibitors; Waldenstrom Macroglobulinemia | 2023 |
Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans | 2019 |
How we manage Bing-Neel syndrome.
Topics: Adenine; Amino Acid Substitution; Brain Neoplasms; Humans; Magnetic Resonance Imaging; Mutation, Mis | 2019 |
What is new in the treatment of Waldenstrom macroglobulinemia?
Topics: Adenine; Antibodies, Monoclonal; Antigens, CD20; Benzamides; Bone Marrow; Disease-Free Survival; Hem | 2019 |
An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Clinical Trials as Topic | 2020 |
The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Development; Drug Resistance, Neoplasm; Humans; P | 2020 |
Emerging drugs for the treatment of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Design; Drug Resistance; Humans; Mutation; Myeloi | 2020 |
[Clonal-related transformation from Waldenström macroglobulinemia to diffuse large B cell lymphoma during the treatment of ibrutinib: a case report and literature review].
Topics: Adenine; Humans; Lymphoma, Large B-Cell, Diffuse; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom M | 2020 |
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides | 2020 |
How to Sequence Therapies in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Bendam | 2021 |
Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Adenine; Adult; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Hu | 2019 |
Ibrutinib in the management of Waldenstrom macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazo | 2019 |
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Topics: Adenine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Pi | 2019 |
Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Topics: Adenine; Drug Resistance, Neoplasm; Humans; Mutation; Neoplasm Proteins; Piperidines; Pyrazoles; Pyr | 2018 |
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Drug Resistance, Neoplasm; Humans; Piperidines; Protei | 2018 |
Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Bone Marrow; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Piperid | 2019 |
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Blood Viscosity; Gene Expressio | 2019 |
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Disease-Free Survival; Humans; Leukemia, Lymphocytic, | 2014 |
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 2014 |
Biology, prognosis, and therapy of Waldenström Macroglobulinemia.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic A | 2015 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho | 2015 |
Ibrutinib for the treatment of Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Drug Approval; Drug Co | 2015 |
Ibrutinib in B lymphoid malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Clinical Trials as Top | 2015 |
[Changes in the prognosis and treatment of Waldenström macroglobulinemia. Literature overview and own experience].
Topics: Adenine; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Topics: Adenine; Animals; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Neoplasms, Ex | 2016 |
Current therapy guidelines for Waldenstrom's macroglobulinaemia.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cli | 2016 |
Future therapeutic options for patients with Waldenström macroglobulinemia.
Topics: Adenine; ADP-ribosyl Cyclase 1; Agammaglobulinaemia Tyrosine Kinase; Clinical Trials as Topic; Human | 2016 |
Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Cyc | 2017 |
Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Genomics; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyri | 2017 |
Targeting of B-cell receptor signalling in B-cell malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Humans | 2017 |
14 trials available for adenine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2022 |
Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Apoptosis; Chromosome Deletion; Chromosomes, Hum | 2020 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2020 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2020 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2020 |
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2020 |
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Topics: Adenine; Adult; Age Factors; Autografts; Disease-Free Survival; Female; Humans; Immunotherapy; Male; | 2020 |
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
Topics: Adenine; Administration, Oral; Adult; Aged; Aged, 80 and over; Area Under Curve; Bupropion; Contrace | 2020 |
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Topics: Adenine; Female; Humans; Male; Middle Aged; Piperidines; Prognosis; Progression-Free Survival; Prosp | 2021 |
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Humans; Middle Aged; | 2021 |
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.
Topics: Adenine; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidi | 2018 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibr | 2018 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibr | 2018 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibr | 2018 |
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibr | 2018 |
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Mutation; Myeloid Differentiation Factor 88; P | 2018 |
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Disease-Free Survival; | 2015 |
Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Pip | 2016 |
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fem | 2017 |
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Topics: Adenine; Aged; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Prot | 2017 |
71 other studies available for adenine and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piper | 2022 |
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piper | 2022 |
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piper | 2022 |
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piper | 2022 |
Plamotamab (XmAb
Topics: Adenine; Humans; Myeloid Differentiation Factor 88; Piperidines; Receptors, CXCR4; Waldenstrom Macro | 2022 |
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Topics: Adenine; Aged; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2022 |
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazo | 2022 |
Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations in Waldenström macroglobulinemia therapy: structural mechanistic insights on the role of fenebrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amino Acids; Arginine; Drug Resistance, Neoplasm; Huma | 2022 |
Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Humans; Piperidines; Waldenstrom Macroglobulinemia | 2023 |
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Diseas | 2020 |
Topics: Adenine; Drug Resistance; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazole | 2019 |
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Autoimmune Diseases of the Ne | 2020 |
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Topics: Adenine; Aged; Dose-Response Relationship, Drug; Humans; Male; Mutation; Myeloid Differentiation Fac | 2020 |
Complete Response of a Young Woman With MYD88
Topics: Adenine; Adolescent; Agammaglobulinaemia Tyrosine Kinase; Female; Humans; Myeloid Differentiation Fa | 2020 |
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piper | 2021 |
Partial responses to ibrutinib in Waldenström macroglobulinaemia - good enough?
Topics: Adenine; Humans; Piperidines; Prognosis; Progression-Free Survival; Pyrimidines; Waldenstrom Macrogl | 2021 |
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Topics: Adenine; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Epigenesi | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chl | 2021 |
The role of ibrutinib in COVID-19 hyperinflammation: A case report.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged, 80 and over; COVID-19; COVID-19 Drug Treatment; | 2021 |
Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision.
Topics: Adenine; Aged; Blood Cell Count; Central Nervous System Neoplasms; Cerebrospinal Fluid; Diagnosis, D | 2021 |
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2022 |
Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; B | 2021 |
Ibrutinib therapy for lymphoplasmacytic lymphoma.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; | 2017 |
Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
Topics: Adenine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; | 2017 |
Ibrutinib-induced acute liver failure.
Topics: Adenine; Biomarkers; Combined Modality Therapy; Female; Humans; Liver Failure, Acute; Middle Aged; P | 2018 |
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Atrial Fibrillation; B-Lympho | 2017 |
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Topics: Adenine; Biomarkers; Chemokine CXCL13; Cytokines; Humans; Immunoglobulin M; Piperidines; Prognosis; | 2017 |
Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Topics: Adenine; Cell Transformation, Neoplastic; Central Nervous System Diseases; Female; Humans; Middle Ag | 2018 |
Recurrent chylothorax: a clinical mystery.
Topics: Adenine; Chylothorax; Female; Humans; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pyrazol | 2017 |
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Topics: Adenine; Aged; Disease Progression; Female; Humans; Immunoglobulin M; Kaplan-Meier Estimate; Male; M | 2018 |
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazole | 2018 |
Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome.
Topics: Adenine; Aged; Brain; Brain Diseases; Humans; Magnetic Resonance Imaging; Male; Piperidines; Pyrazol | 2018 |
Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2018 |
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Topics: Adenine; ADP-ribosyl Cyclase 1; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplast | 2018 |
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Topics: Adenine; Adult; Aged; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; M | 2019 |
First-line ibrutinib for Bing-Neel syndrome.
Topics: Adenine; Aged; Brain; Humans; Magnetic Resonance Imaging; Male; Piperidines; Pyrazoles; Pyrimidines; | 2018 |
Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Topics: Adenine; Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Magnetic Resonance Imaging | 2020 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Precision therapies take aim at non-Hodgkin's lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Disease Models, Animal; Dogs; Drug Approval; | 2018 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Waldenstrom Macroglobulinemia | 2018 |
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Invasive Fungal Infe | 2019 |
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
Topics: Adenine; Adult; Aged; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperidines; Pyrazol | 2019 |
SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS.
Topics: Adenine; Humans; Piperidines; Retinal Detachment; Treatment Outcome; Waldenstrom Macroglobulinemia | 2021 |
ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Topics: Adenine; Clinical Trials as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimi | 2016 |
Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.
Topics: Adenine; Brain Diseases; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazole | 2019 |
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Topics: Adenine; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2019 |
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Topics: Adenine; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2019 |
Rare case of Bing-Neel syndrome treated successfully with ibrutinib.
Topics: Adenine; Brain; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mutation; Myeloid Different | 2019 |
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Male; Middle Aged; M | 2019 |
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Topics: Adenine; Death, Sudden, Cardiac; Electrocardiography; Humans; Male; Middle Aged; Piperidines; Protei | 2019 |
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-R | 2015 |
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Topics: Adenine; Amino Acid Substitution; Apoptosis; Cell Survival; Chemokine CXCL12; Codon, Nonsense; Drug | 2015 |
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; B | 2015 |
Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy P | 2015 |
MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
Topics: Adenine; Humans; Mutation; Myeloid Differentiation Factor 88; Piperidines; Pyrazoles; Pyrimidines; W | 2015 |
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor | 2016 |
Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.
Topics: Adenine; Aged; Central Nervous System Diseases; Female; Humans; Immunoglobulin M; Leukocyte Count; M | 2016 |
[Ibrutinib prescription in B-cell lymphoid neoplasms].
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; B-Lymphocytes; Clinical Trials as Topic; Drug Resistan | 2016 |
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
Topics: Adenine; Amino Acid Substitution; Female; Humans; Immunoglobulin G; Leucine; Mutation, Missense; Mye | 2016 |
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Leukemi | 2016 |
Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Topics: Adenine; Aged; Anemia, Hemolytic, Autoimmune; Humans; Male; Piperidines; Protein Kinase Inhibitors; | 2016 |
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Topics: Acrylamides; Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; B-Lymphocytes; Caspase 3; Cell D | 2016 |
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
Topics: Adenine; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Central Nervous System Neoplasms; H | 2017 |
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Topics: Adenine; Apoptosis; Azepines; Benzylidene Compounds; Bortezomib; Cell Line, Tumor; Cell Survival; De | 2016 |
Learning from Waldenstrom Macroglobulinemia.
Topics: Adenine; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase II as Topic; Humans; Pipe | 2016 |
Ibrutinib in Waldenström's macroglobulinemia: revamping the landscape.
Topics: Adenine; Humans; Piperidines; Pyrazoles; Pyrimidines; Waldenstrom Macroglobulinemia | 2017 |
A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia.
Topics: Adenine; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Cardiotonic Agents; Electric Cou | 2017 |
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Topics: Adenine; Advisory Committees; Antineoplastic Agents; Australia; Bendamustine Hydrochloride; Bone Mar | 2017 |
Bruton's tyrosine kinase: oncotarget in myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Growth Processes; Disease Models, Animal | 2012 |
Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis.
Topics: Adenine; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Female; Hepatitis B | 2007 |